Sargent Bickham Lagudis LLC Eli Lilly & CO Transaction History

Sargent Bickham Lagudis LLC

$1.22 Billion
Q4 2022

A detailed history of Sargent Bickham Lagudis LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Sargent Bickham Lagudis LLC holds 11,562 shares of LLY stock, worth $9.68 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares

11,562

Previous 10,919 5.89%

Holding current value

$9.68 Million

Previous $3.53 Million 19.77%

% of portfolio

0.35%

Previous 0.32%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 23, 2023	BUY	$321.55 - $374.67 $206,756 - $240,912	643 Added 5.89%	11,562 $0
Q3 2022 Oct 27, 2022	BUY	$296.48 - $337.87 $282,841 - $322,327	954 Added 9.57%	10,919 $3.53 Million
Q2 2022 Jul 13, 2022	SELL	$278.73 - $327.27 $299,077 - $351,160	-1,073 Reduced 9.72%	9,965 $3.23 Million
Q1 2022 Apr 27, 2022	BUY	$234.69 - $291.66 $297,586 - $369,824	1,268 Added 12.98%	11,038 $3.16 Million
Q4 2021 Jan 18, 2022	BUY	$224.85 - $279.04 $1.93 Million - $2.39 Million	8,572 Added 715.53%	9,770 $2.7 Million
Q3 2021 Nov 05, 2021	BUY	$221.6 - $272.71 $68,696 - $84,540	310 Added 34.91%	1,198 $277,000
Q2 2021 Jul 19, 2021	BUY	$180.55 - $233.54 $22,568 - $29,192	125 Added 16.38%	888 $204,000
Q1 2021 May 24, 2021	BUY	$164.32 - $212.72 $13,967 - $18,081	85 Added 12.54%	763 $143,000
Q4 2020 May 24, 2021	SELL	$130.46 - $172.63 $11,089 - $14,673	-85 Reduced 11.14%	678 $115,000
Q4 2020 May 24, 2021	BUY	$130.46 - $172.63 $13,306 - $17,608	102 Added 15.43%	763 $143,000
Q1 2020 Sep 07, 2021	SELL	$119.05 - $147.35 $26,071 - $32,269	-219 Reduced 24.89%	661 $92,000
Q4 2019 Sep 14, 2021	BUY	$106.92 - $132.43 $23,629 - $29,267	221 Added 33.54%	880 $116,000
Q3 2019 Sep 14, 2021	BUY	$106.79 - $116.16 $18,367 - $19,979	172 Added 35.32%	659 $74,000
Q2 2019 Sep 13, 2021	BUY	$110.79 - $129.32 $110 - $129	1 Added 0.21%	487 $54,000
Q1 2019 Sep 13, 2021	SELL	$111.31 - $131.02 $14,025 - $16,508	-126 Reduced 20.59%	486 $63,000
Q4 2018 Sep 13, 2021	SELL	$105.9 - $118.64 $31,558 - $35,354	-298 Reduced 32.75%	612 $71,000
Q3 2018 Sep 13, 2021	BUY	$85.86 - $107.31 $171 - $214	2 Added 0.22%	910 $98,000
Q2 2018 Sep 13, 2021	SELL	$75.7 - $86.88 $11,203 - $12,858	-148 Reduced 14.02%	908 $78,000
Q1 2018 Sep 13, 2021	SELL	$74.21 - $87.6 $19,665 - $23,214	-265 Reduced 20.06%	1,056 $82,000
Q4 2017 Sep 13, 2021	BUY	$81.94 - $87.89 $10,324 - $11,074	126 Added 10.54%	1,321 $112,000
Q3 2017 Sep 13, 2021	BUY	$77.07 - $85.54 $46,550 - $51,666	604 Added 102.2%	1,195 $102,000
Q2 2017 Sep 13, 2021	BUY	N/A	65 Added 12.36%	591 $49,000
Q3 2016 Sep 13, 2021	SELL	N/A	-350 Reduced 39.95%	526 $42,000
Q1 2016 Sep 07, 2021	BUY	N/A	876	876 $63,000

Others Institutions Holding LLY

# of Institutions

4,290

Shares Held

757M

Call Options Held

10.2M

Put Options Held

11.4M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $796B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Bickham Lagudis LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Bickham Lagudis LLC with notifications on news.

Account

Sargent Bickham Lagudis LLC Eli Lilly & CO Transaction History